SCHEMBL4906222

SCHEMBL4906222

COc1cc(-c2nc(NC3CC3)nc(Cl)c2C#N)ccc1C(F)(F)F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.45
▸ HPGD P15428 3/20 0.45
▸ KDM4E B2RXH2 2/20 0.45
▸ MAPT P10636 2/20 0.45
▸ LMNA P02545 1/20 0.45
▸ CYP1A2 P05177 1/20 0.45
▸ CYP3A4 P08684 1/20 0.45
▸ CYP2D6 P10635 1/20 0.45
▸ CYP2C9 P11712 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ ULK1 O75385 2/20 0.41
▸ ULK2 Q8IYT8 2/20 0.41
▸ ADORA1 P30542 5/20 0.40
▸ ADORA2A P29274 3/20 0.40
▸ AGER Q15109 1/20 0.38
▸ GRM5 P41594 1/20 0.37
▸ KDM1A O60341 1/20 0.37
▸ PDE4B Q07343 1/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4900864 0.89 MAPT (0.45) ALDH1A1HPGDKDM4EMAPTLMNA
SCHEMBL4898198 0.86 HPGD (0.41) ALDH1A1HPGDKDM4EMAPTLMNA
SCHEMBL4909720 0.80 MAPT (0.51) ALDH1A1HPGDKDM4EMAPTLMNA
SCHEMBL4907303 0.80 CTSS (0.47) CYP1A2CYP2C9CYP2C19ADORA1ADORA2A
SCHEMBL4912631 0.79 ADORA2A (0.57) ALDH1A1HPGDMAPTLMNACYP1A2
SCHEMBL4898439 0.78 KDM1A (0.52) CYP1A2CYP2C9CYP2C19ADORA1ADORA2A
SCHEMBL4907249 0.78 KMT2A (0.41) ALDH1A1HPGDCYP1A2CYP2C9CYP2C19
SCHEMBL4906201 0.76 KMT2A (0.55) ALDH1A1HPGDCYP1A2CYP2C9CYP2C19
SCHEMBL4907027 0.76 ADORA2A (0.47) ALDH1A1HPGDKDM4EMAPTLMNA
SCHEMBL4899212 0.76 KDM1A (0.47) ALDH1A1HPGDKDM4ELMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1984377-A2 INHIBITORS OF TNF ALPHA , PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH Signal Pharmaceuticals LLC (US) 2008-10-29 — — EP disclosed
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith MCKENNA JEFFREY M 2008-01-03 — — US disclosed
WO-2007084560-A2 INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH SIGNAL PHARMACEUTICALS, LLC (US) 2007-07-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith PDE4A, PDE4B, BRAF ALDH1A1 1662/4885HPGD 1654/4885KDM4E 2429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback